Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche recall

This article was originally published in The Gray Sheet

Executive Summary

Cobas Taqman and Taqman 48 analyzer Class I recall is ongoing, after the discovery that some analyzers have an "improperly seated fiber optic cable," which could falsely elevate patient hepatitis B and C virus test results. Because physicians stop or change treatment upon finding elevated test results - which show patients failing to respond to treatment - disease progression or death could result in some cases. Roche is considering redesigning the optic cable, and says its field service engineers have inspected 100 analyzers for correct cable seating. The Taqman action is a further example of an increased number of Class I recalls compared with prior years (1"The Gray Sheet" July 19, 2004, p. 16)...
Advertisement

Related Content

Zeiss Visulink Reflects Rise In Device Class I Recall Notifications
Zeiss Visulink Reflects Rise In Device Class I Recall Notifications
Advertisement
UsernamePublicRestriction

Register

MT020631

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel